Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:01:07.225Z.
Calculation as of: 2026-10-06T20:01:07.225Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d465a3cb364884174ea279f6e96e1b331d3038a7942601b23d7c9becb19c45da
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Avalyn Pharma Inc. Common Stock
Market Cap
$1.13B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
Price/OCF Ratio
180.80
TTM Avg
131.82
3Y Avg
1823.85
5Y Avg
1138.24
Market Cap
$1.10B
Price/OCF Ratio
N/A
TTM Avg
73.98
3Y Avg
165.41
5Y Avg
108.12
Market Cap
$1.10B
Price/OCF Ratio
N/A
TTM Avg
42.70
3Y Avg
80.31
5Y Avg
125.63
Market Cap
$1.13B
Price/OCF Ratio
5.63
TTM Avg
5.50
3Y Avg
12.06
5Y Avg
21.65
Market Cap
$1.09B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.14B
Price/OCF Ratio
6.19
TTM Avg
6.67
3Y Avg
9.62
5Y Avg
13.32
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.13B | N/A | N/A | N/A | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.11B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 180.80 | 131.82 | 1823.85 | 1138.24 |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.10B | N/A | 73.98 | 165.41 | 108.12 |
| STAAR Surgical Company (STAA)vs › | $1.10B | N/A | 42.70 | 80.31 | 125.63 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | 5.63 | 5.50 | 12.06 | 21.65 |
| Nektar Therapeutics (NKTR)vs › | $1.14B | N/A | 9.13 | 9.13 | 9.13 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 6.19 | 6.67 | 9.62 | 13.32 |
| OPKO Health, Inc. (OPK)vs › | $1.09B | N/A | 31.85 | 37.88 | 115.22 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
